Vitamin D deficiency is associated with cardiometabolic risk factors (eg, hypertension, insulin resistance, type 2 diabetes mellitus, obesity, and dyslipidemia). We studied 50 obese patients (body mass index [BMI]: 43.5 ± 9.2 kg/m2) and 36 normal weight participants (BMI: 22.6 ± 1.9 kg/m2). The prevalence of vitamin D deficiency (25-hydroxyvitamin D, 25(OH)D < 50 nmol/L) was 88% among obese patients and 31% among nonobese individuals; 25(OH)D levels were lower in the obese group (27.3 ± 13.7 vs 64.6 ± 21.3 nmol/L; P < .001). There was a negative correlation between vitamin D level and anthropometric indicators of obesity: BMI (r = −0.64; P < .001), waist circumference (r = −0.59; P < .001), and body fat percentage (r = −0.64; P < .001) as well as with fasting plasma insulin (r = −0.35; P < .001) and homeostasis model assessment of insulin resistance (r = −0.35; P < .001). In conclusion, we observed a higher prevalence of vitamin D deficiency among obese participants and this was associated with a proatherogenic cardiometabolic risk profile.
TsigosCHainerVBasdevantA. Management of obesity in adults: European clinical practice guidelines. Obes Facts. 2008;1(2):106–116.
2.
GrujicVDragnicNRadicIHarhajiSSusnjevicS. Overweight and obesity among adults in Serbia: results from the national health survey. Eat Weight Disord. 2010;15(1-2):e34–e42.
3.
MustASpadanoJCoakleyEHFieldAEColditzGDietzWH. The disease burden associated with overweight and obesity. JAMA. 1999;282(16):1523–1529.
4.
National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. Bethesda MD: NIH publication; 1998.
5.
KatsikiNAthyrosVGKaragiannisAMikhailidisDP. Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview. Curr Vasc Pharmacol. 2014;12(4):627–641.
6.
KienreichKTomaschitzAVerheyenN. Vitamin D and cardiovascular disease. Nutrients. 2013;5(8):3005–3021.
7.
Abu El MaatyMAHassaneinSIHanafiRSGadMZ. Insights on vitamin D's role in cardiovascular disease: investigating the association of 25-hydroxyvitamin D with the dimethylated arginines. J Nutr Sci Vitaminol (Tokyo). 2013;59(3):172–177.
8.
SiadatZDKianiKSadeghiMShariatASFarajzadeganZKheirmandM. Association of vitamin D deficiency and coronary artery disease with cardiovascular risk factors. J Res Med Sci. 2012;17(11):1052–1055.
9.
FormanJPCurhanGCTaylorEN. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension. 2008;52(5):828–832.
10.
KhanHKunutsorSFrancoOHChowdhuryR. Vitamin D, type 2 diabetes and other metabolic outcomes: a systematic review and meta-analysis of prospective studies. Proc Nutr Soc. 2013;72(1):89–97.
11.
FordESAjaniUAMcguireLCLiuS. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care. 2005;28(5):1228–1230.
12.
HypponenEBoucherBJBerryDJPowerC25-hydroxyvitaminD, IGF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British birth cohort. Diabetes. 2008;57(2):298–305.
13.
CimbekAGursoyGKirnapNG. Relation of obesity with serum 25 hydroxy vitamin D3 levels in type 2 diabetic patients. J Res Med Sci. 2012;17(12):1119–1123.
14.
Hossein-NezhadAHolickMF. Vitamin D for health: a global perspective. Mayo Clin Proc. 2013;88(7):720–755.
15.
ManchandaPKBidHK. Vitamin D receptor and type 2 diabetes mellitus: growing therapeutic opportunities. Indian J Hum Genet. 2012;18(3):274–275.
16.
HolickMF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–281.
17.
ChiuKCChuAGoVLSaadMF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004;79(5):820–825.
18.
HeaneyRPFrenchCBNguyenS. A novel approach localizes the association of vitamin D status with insulin resistance to one region of the 25-hydroxyvitamin D continuum. Adv Nutr. 2013;4(3):303–310.
19.
SchottkerBHerderCRothenbacherDPernaLMullerHBrennerH. Serum 25-hydroxyvitamin D levels and incident diabetes mellitus type 2: a competing risk analysis in a large population-based cohort of older adults. Eur J Epidemiol. 2013;28(3):267–275.
20.
HutchinsonMSFigenschauYAlmasBNjolstadIJordeR. Serum 25-hydroxyvitamin D levels in subjects with reduced glucose tolerance and type 2 diabetes - the Tromso OGTT-study. Int J Vitam Nutr Res. 2011;81(5):317–327.
21.
NazarianSSt PeterJVBostonRCJonesSAMariashCN. Vitamin D3 supplementation improves insulin sensitivity in subjects with impaired fasting glucose. Transl Res. 2011;158(5):276–281.
22.
LielYUlmerESharyJHollisBWBellNH. Low circulating vitamin D in obesity. Calcif Tissue Int. 1988;43(4):199–201.
23.
HyldstrupLAndersenTMcnairPBreumLTransbolI. Bone metabolism in obesity: changes related to severe overweight and dietary weight reduction. Acta Endocrinol (Copenh). 1993;129(5):393–398.
24.
WortsmanJMatsuokaLYChenTCLuZHolickMF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72(3):690–693.
25.
ParikhSJEdelmanMUwaifoGI. The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab. 2004;89(3):1196–1199.
26.
McgillATStewartJMLithanderFEStrikCMPoppittSD. Relationships of low serum vitamin D3 with anthropometry and markers of the metabolic syndrome and diabetes in overweight and obesity. Nutr J. 2008;7:1–5.
27.
FriedewaldWTLevyRIFredricksonDS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
28.
MatthewsDRHoskerJPRudenskiASNaylorBATreacherDFTurnerRC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419.
29.
TaheriESaedisomeoliaADjalaliMQorbaniMMadani CiviM. The relationship between serum 25-hydroxy vitamin D concentration and obesity in type 2 diabetic patients and healthy subjects. J Diabetes Metab Disord. 2012;11(1):16.
30.
De PergolaGNittiABartolomeoN. Possible role of hyperinsulinemia and insulin resistance in lower vitamin D levels in overweight and obese patients. Biomed Res Int. 2013;2013:921348.
31.
BuffingtonCWalkerBCowanGSJrScruggsD. Vitamin D deficiency in the morbidly obese. Obes Surg. 1993;3(4):421–424.
32.
HeyHStokholmKHLundBLundBSorensenOH. Vitamin D deficiency in obese patients and changes in circulating vitamin D metabolites following jejunoileal bypass. Int J Obes. 1982;6(5):473–479.
33.
ArunabhSPollackSYehJAloiaJF. Body fat content and 25-hydroxyvitamin D levels in healthy women. J Clin Endocrinol Metab. 2003;88(1):157–161.
34.
SalekzamaniSNeyestaniTRAlavi-MajdH. Is vitamin D status a determining factor for metabolic syndrome? A case-control study. Diabetes Metab Syndr Obes. 2011;4:205–212.
35.
HolickMF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004;80(6 suppl):1678S–1688S.
36.
SneveMFigenschauYJordeR. Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects. Eur J Endocrinol. 2008;159(6):675–684.
37.
Botella-CarreteroJIAlvarez-BlascoFVillafruelaJJBalsaJAVazquezCEscobar-MorrealeHF. Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity. Clin Nutr. 2007;26(5):573–580.
38.
PilzSTomaschitzARitzEPieberTR. Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol. 2009;6(10):621–630.
39.
WambergLKampmannUStodkilde-JorgensenHRejnmarkLPedersenSBRichelsenB. Effects of vitamin D supplementation on body fat accumulation, inflammation, and metabolic risk factors in obese adults with low vitamin D levels - results from a randomized trial. Eur J Intern Med. 2013;24(7):644–649.
40.
MajorGCAlarieFDoreJPhouttamaSTremblayA. Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr. 2007;85(1):54–59.
41.
ChengSMassaroJMFoxCS. Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. Diabetes. 2010;59(1):242–248.
PittasAGLauJHuFBDawson-HughesB. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007;92(6):2017–2029.
44.
DobnigHPilzSScharnaglH. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168(12):1340–1349.
45.
ReisJPVon MuhlenDMillerER3 rdMichosEDAppelLJ. Vitamin D status and cardiometabolic risk factors in the United States adolescent population. Pediatrics. 2009;124(3):e371–e379.
46.
PooleKELoveridgeNBarkerPJ. Reduced vitamin D in acute stroke. Stroke. 2006;37(1):243–245.
47.
KatsikiNAthyrosVGKaragiannisAMikhailidisDP. Vitamin D deficiency, statin-related myopathy and other links with vascular risk. Curr Med Res Opin. 2011;27(9):1691–1692.
48.
GiovannucciELiuYHollisBW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008;168(11):1174–1180.
49.
WangTJPencinaMJBoothSL. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503–511.
50.
De LorenzoAMartinoliRVaiaFDi RenzoL. Normal weight obese (NWO) women: an evaluation of a candidate new syndrome. Nutr Metab Cardiovasc Dis. 2006;16(8):513–523.
51.
García-BailoBDa CostaLAAroraPKarmaliMEl-SohemyABadawiA. Plasma vitamin D and biomarkers of cardiometabolic disease risk in adult Canadians, 2007-2009. Prev Chronic Dis. 2013;10:E91.
